Active-ingredient Dossier
Doxorubicin Hydrochloride
Active-ingredient Dossier for Doxorubicin Hydrochloride (anthracycline chemotherapy agent). Australian brands, products, PBS listings, PBAC outcomes —…
- Brand: ADRIAMYCIN
- Brand: CAELYX
- Brand: DOXORUBICIN ACCORD
- Brand: LIPOSOMAL
- Brand: Doxorubicin
- Brand: Doxorubicin
- Therapeutic area: Oncology
What is
Doxorubicin Hydrochloride Doxorubicin Hydrochloride is an anthracycline chemotherapy agent.
Australian brands containing
Doxorubicin Hydrochloride — ADRIAMYCIN — Doxorubicin — CAELYX — DOXORUBICIN ACCORD — LIPOSOMAL
Therapeutic areas
Doxorubicin Hydrochloride is registered in oncology (4 brands) and complementary medicine (2 brands).
Sponsor landscape
The ingredient is marketed by six sponsors: Pfizer, Baxter Healthcare, Pfizer (Perth), Hospira, Accord Healthcare, and Sun Pharma.
PBS and regulatory activity
One brand containing Doxorubicin Hydrochloride has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome on record is from 1 September 2021.